天竺政府相关负责人指出："国医医联在中医药成果转化与产业链整合方面具备显著优势，其商业模式 与技术能力高度契合顺义区大健康产业发展规划。通过北京国门同翔股权投资基金的战略投入，将有力 推动国医医联在区域内实现技术落地、产业融合与服务升级，助力中医药守正创新与区域经济高质量发 展。" 国医医联创始人、董事长兼CEO赵鑫女士表示："感谢天竺政府及北京国门同翔股权投资基金对国医医 联的认可与支持。本轮资金将聚焦于顺义区中医药成果转化场景建设，进一步提升中医药服务的可及性 与精准性。我们期待携手地方政府，共同打造区域中医药创新转化示范模式。" 此次合作标志着国医医联在政策协同与区域资源整合方面迈出关键一步。公司将继续依托"技术+运营 +渠道"一体化转化体系，加速中医药从临床成果走向规模化应用，为全民健康与中医药产业振兴注入 持续动力。 投资界2月13日消息，近日，北京国医医联健康科技有限公司（下称"国医医联"）获得由北京市顺义区 天竺政府主导设立的"北京国门同翔股权投资基金"投资，公司本轮估值达2亿元。此次合作将重点支持 国医医联在顺义区深化中医药临床名方转化体系建设，双方共同携手打造一个立足顺义天竺，辐射全 国，并 ...

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing significant opportunities, driven by policy support and strong performance in the stock market [1][2]. Market Performance - On August 1, the A-share market saw a mixed performance with the Shanghai Composite Index down 0.37%, Shenzhen Component down 0.17%, and ChiNext down 0.24%, while over 3,300 stocks rose [1]. - The TCM sector witnessed a surge, with the Shenwan TCM Index rising by 1.78%, placing it among the top-performing secondary industry indices [2]. Policy and Industry Developments - The establishment of the Yangtze River Delta TCM Concept Verification and Achievement Transformation Center in Shanghai aims to enhance the commercialization of TCM research [2]. - The State Council's 2025 policy emphasizes the protection and utilization of TCM resources, indicating a supportive regulatory environment for the industry [2]. Company Performance - Notable companies such as Darentang, Jilin Aodong, and Buchang Pharmaceutical reported significant net profit growth, with Darentang's net profit expected to reach between 18.4 billion to 20 billion yuan, marking a year-on-year increase of 180% to 204% [4][5]. - Jilin Aodong anticipates a net profit of approximately 12.36 billion to 12.9 billion yuan, reflecting a year-on-year growth of 130% to 140% [5]. - Tianmu Pharmaceutical successfully turned a profit during the reporting period, driven by enhanced market strategies and sales [5]. Financial Highlights - The following companies reported substantial net profit growth in the first half of 2025: - Darentang: 19.2 billion yuan, up 192% [6] - Jilin Aodong: 12.63 billion yuan, up 135% [6] - Buchang Pharmaceutical: 5.98 billion yuan, up 158.41% [6] - The overall performance of TCM companies indicates a strong recovery and growth trajectory, supported by favorable market conditions and policy initiatives [4][5].

Core Viewpoint - On the first trading day of August, China's A-shares experienced a correction with major indices declining, but the traditional Chinese medicine sector showed resilience, rising significantly [1] Market Performance - The traditional Chinese medicine sector increased by 3.39%, leading all industry sectors in A-shares [1] - Notable individual stocks included Weikang Pharmaceutical, Tianmu Pharmaceutical, Xintian Pharmaceutical, and Huason Pharmaceutical, with Weikang Pharmaceutical achieving approximately a 20% increase [1] - The Shanghai Composite Index closed at 3559 points, down 0.37%; the Shenzhen Component Index closed at 10991 points, down 0.17%; and the ChiNext Index closed at 2322 points, down 0.24% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 15,984 billion RMB, a decrease of about 3,377 billion RMB compared to the previous trading day [1] Industry Developments - The Long Triangle Traditional Chinese Medicine Concept Verification and Achievement Transformation Center was officially launched, aiming to address early bottlenecks in the transformation of traditional Chinese medicine achievements [1] Analyst Insights - According to Guo Yiming, Director of Investment Advisory at Jifeng Investment Consulting, the decline in A-shares on August 1 was primarily a technical adjustment due to the indices reaching a phase high, coupled with profit-taking [1] - The overall outlook remains positive, with the fundamental recovery of the Chinese economy, improved market liquidity, and supportive policies indicating limited downward space for the indices in the future [1]

Core Insights - Shanghai Agricultural Science and Technology Innovation Valley has achieved significant progress in its first year, with total investments exceeding 20 billion yuan, focusing on future industries such as plant extraction [1][2] - The establishment of the Yangtze River Delta Traditional Chinese Medicine Concept Verification and Achievement Transformation Center aims to enhance the conversion of TCM research into market-ready products, supported by national resources and partnerships with leading pharmaceutical companies [1] - The launch of the Shanghai Agricultural Science and Technology Innovation Valley Joint Innovation Center promotes the integration of academia, industry, and research, attracting new enterprises in smart equipment, biotechnology, and digital agriculture [2] Investment and Development - Total investment in the Shanghai Agricultural Science and Technology Innovation Valley has surpassed 20 billion yuan, indicating strong financial backing for agricultural innovation [1] - The initiative includes 31 major projects in plant extraction and aims to streamline the entire process from research and development to industrialization [1] Strategic Initiatives - The center will implement a dual support mechanism combining "verification assessment + resource integration" to facilitate the development of new TCM drugs and food products [1] - The "Four Batch" project aims to establish significant technological infrastructure, publish technology lists, form industry innovation coalitions, and launch high-value plant extraction products [2]